Related Experiment Video

Updated: Aug 27, 2025

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.7K

Bacterial outer membrane vesicle-based cancer nanovaccines

Xiaoyu Gao1,2, Qingqing Feng1, Jing Wang3

  • 1CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China.

Cancer Biology & Medicine
|September 29, 2022
PubMed

Insights

Outer membrane vesicles (OMVs) are emerging as a promising nanocarrier for tumor vaccines, enhancing anti-tumor immune responses. Their natural adjuvant properties and engineerability make them ideal for developing effective tumor nanovaccines.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology
  • Nanotechnology

Background:

  • Tumor vaccines are crucial for personalized cancer immunotherapy, aiming to elicit T cell responses against tumor cells.
  • Enhancing the immunogenicity of tumor antigens often requires immune adjuvants and nanocarriers.
  • Outer membrane vesicles (OMVs) from Gram-negative bacteria are gaining traction as versatile nanocarrier platforms for tumor vaccines.

Purpose of the Study:

  • To review recent advancements and future directions in the development of outer membrane vesicle (OMV)-based tumor nanovaccines.
  • To highlight the potential of OMVs as integrated nanocarriers and immune adjuvants for cancer immunotherapy.

Main Methods:

  • Review of current literature on OMV applications in tumor nanovaccines.
  • Analysis of OMV characteristics, including strain selection, heterogeneity, and antigen loading.
  • Evaluation of OMV immunogenicity, safety, and scalability for mass production.

Main Results:

  • OMVs possess inherent adjuvant properties due to pathogen-associated molecular patterns.
  • Genetic engineering of bacteria allows functional modification of OMVs for targeted delivery.
  • Key considerations for OMV-based nanovaccines include strain selection, antigen loading strategies, and production scalability.

Conclusions:

  • OMVs represent a promising platform for developing advanced tumor nanovaccines with enhanced immunogenicity and safety.
  • Further research into OMV engineering, production, and clinical translation is warranted for effective cancer immunotherapy.
Keywords:
Cancercancer vaccinesnanocarriersouter membrane vesiclestumor antigen

More Related Videos

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

1.8K
Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.1K

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
493
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
643
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.3K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
207
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
49.3K